The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model

Piotr Czauderna, Beate Haeberle, Eiso Hiyama, Arun Rangaswami, Mark Krailo, Rudolf Maibach, Eugenia Rinaldi, Yurong Feng, Daniel Aronson, Marcio Malogolowkin, Kenichi Yoshimura, Ivo Leuschner, Dolores Lopez-Terrada, Tomoro Hishiki, Giorgio Perilongo, Dietrich Von Schweinitz, Irene Schmid, Kenichiro Watanabe, Marisa Derosa, Rebecka Meyers

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Introduction Contemporary state-of-the-art management of cancer is increasingly defined by individualized treatment strategies. For very rare tumors, like hepatoblastoma, the development of biologic markers, and the identification of reliable prognostic risk factors for tailoring treatment, remains very challenging. The Children's Hepatic tumors International Collaboration (CHIC) is a novel international response to this challenge. Methods Four multicenter trial groups in the world, who have performed prospective controlled studies of hepatoblastoma over the past two decades (COG; SIOPEL; GPOH; and JPLT), joined forces to form the CHIC consortium. With the support of the data management group CINECA, CHIC developed a centralized online platform where data from eight completed hepatoblastoma trials were merged to form a database of 1605 hepatoblastoma cases treated between 1988 and 2008. The resulting dataset is described and the relationships between selected patient and tumor characteristics, and risk for adverse disease outcome (event-free survival; EFS) are examined. Results Significantly increased risk for EFS-event was noted for advanced PRETEXT group, macrovascular venous or portal involvement, contiguous extrahepatic disease, primary tumor multifocality and tumor rupture at enrollment. Higher age (≥8 years), low AFP (<100 ng/ml) and metastatic disease were associated with the worst outcome. Conclusion We have identified novel prognostic factors for hepatoblastoma, as well as confirmed established factors, that will be used to develop a future common global risk stratification system. The mechanics of developing the globally accessible web-based portal, building and refining the database, and performing this first statistical analysis has laid the foundation for future collaborative efforts. This is an important step for refining of the risk based grouping and approach to future treatment stratification, thus we think our collaboration offers a template for others to follow in the study of rare tumors and diseases.

Original languageEnglish (US)
Pages (from-to)92-101
Number of pages10
JournalEuropean Journal of Cancer
Volume52
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Hepatoblastoma
Databases
Liver
Research
Neoplasms
Rare Diseases
Mechanics
Multicenter Studies
Disease-Free Survival
Rupture
Therapeutics
Biomarkers
Prospective Studies

Keywords

  • Chemotherapy
  • Hepatoblastoma
  • Pathology
  • Risk stratification

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Children's Hepatic tumors International Collaboration (CHIC) : Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. / Czauderna, Piotr; Haeberle, Beate; Hiyama, Eiso; Rangaswami, Arun; Krailo, Mark; Maibach, Rudolf; Rinaldi, Eugenia; Feng, Yurong; Aronson, Daniel; Malogolowkin, Marcio; Yoshimura, Kenichi; Leuschner, Ivo; Lopez-Terrada, Dolores; Hishiki, Tomoro; Perilongo, Giorgio; Von Schweinitz, Dietrich; Schmid, Irene; Watanabe, Kenichiro; Derosa, Marisa; Meyers, Rebecka.

In: European Journal of Cancer, Vol. 52, 01.01.2016, p. 92-101.

Research output: Contribution to journalArticle

Czauderna, P, Haeberle, B, Hiyama, E, Rangaswami, A, Krailo, M, Maibach, R, Rinaldi, E, Feng, Y, Aronson, D, Malogolowkin, M, Yoshimura, K, Leuschner, I, Lopez-Terrada, D, Hishiki, T, Perilongo, G, Von Schweinitz, D, Schmid, I, Watanabe, K, Derosa, M & Meyers, R 2016, 'The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model', European Journal of Cancer, vol. 52, pp. 92-101. https://doi.org/10.1016/j.ejca.2015.09.023
Czauderna, Piotr ; Haeberle, Beate ; Hiyama, Eiso ; Rangaswami, Arun ; Krailo, Mark ; Maibach, Rudolf ; Rinaldi, Eugenia ; Feng, Yurong ; Aronson, Daniel ; Malogolowkin, Marcio ; Yoshimura, Kenichi ; Leuschner, Ivo ; Lopez-Terrada, Dolores ; Hishiki, Tomoro ; Perilongo, Giorgio ; Von Schweinitz, Dietrich ; Schmid, Irene ; Watanabe, Kenichiro ; Derosa, Marisa ; Meyers, Rebecka. / The Children's Hepatic tumors International Collaboration (CHIC) : Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. In: European Journal of Cancer. 2016 ; Vol. 52. pp. 92-101.
@article{7cd23707183c4ed583189f62f4df72e3,
title = "The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model",
abstract = "Introduction Contemporary state-of-the-art management of cancer is increasingly defined by individualized treatment strategies. For very rare tumors, like hepatoblastoma, the development of biologic markers, and the identification of reliable prognostic risk factors for tailoring treatment, remains very challenging. The Children's Hepatic tumors International Collaboration (CHIC) is a novel international response to this challenge. Methods Four multicenter trial groups in the world, who have performed prospective controlled studies of hepatoblastoma over the past two decades (COG; SIOPEL; GPOH; and JPLT), joined forces to form the CHIC consortium. With the support of the data management group CINECA, CHIC developed a centralized online platform where data from eight completed hepatoblastoma trials were merged to form a database of 1605 hepatoblastoma cases treated between 1988 and 2008. The resulting dataset is described and the relationships between selected patient and tumor characteristics, and risk for adverse disease outcome (event-free survival; EFS) are examined. Results Significantly increased risk for EFS-event was noted for advanced PRETEXT group, macrovascular venous or portal involvement, contiguous extrahepatic disease, primary tumor multifocality and tumor rupture at enrollment. Higher age (≥8 years), low AFP (<100 ng/ml) and metastatic disease were associated with the worst outcome. Conclusion We have identified novel prognostic factors for hepatoblastoma, as well as confirmed established factors, that will be used to develop a future common global risk stratification system. The mechanics of developing the globally accessible web-based portal, building and refining the database, and performing this first statistical analysis has laid the foundation for future collaborative efforts. This is an important step for refining of the risk based grouping and approach to future treatment stratification, thus we think our collaboration offers a template for others to follow in the study of rare tumors and diseases.",
keywords = "Chemotherapy, Hepatoblastoma, Pathology, Risk stratification",
author = "Piotr Czauderna and Beate Haeberle and Eiso Hiyama and Arun Rangaswami and Mark Krailo and Rudolf Maibach and Eugenia Rinaldi and Yurong Feng and Daniel Aronson and Marcio Malogolowkin and Kenichi Yoshimura and Ivo Leuschner and Dolores Lopez-Terrada and Tomoro Hishiki and Giorgio Perilongo and {Von Schweinitz}, Dietrich and Irene Schmid and Kenichiro Watanabe and Marisa Derosa and Rebecka Meyers",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2015.09.023",
language = "English (US)",
volume = "52",
pages = "92--101",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The Children's Hepatic tumors International Collaboration (CHIC)

T2 - Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model

AU - Czauderna, Piotr

AU - Haeberle, Beate

AU - Hiyama, Eiso

AU - Rangaswami, Arun

AU - Krailo, Mark

AU - Maibach, Rudolf

AU - Rinaldi, Eugenia

AU - Feng, Yurong

AU - Aronson, Daniel

AU - Malogolowkin, Marcio

AU - Yoshimura, Kenichi

AU - Leuschner, Ivo

AU - Lopez-Terrada, Dolores

AU - Hishiki, Tomoro

AU - Perilongo, Giorgio

AU - Von Schweinitz, Dietrich

AU - Schmid, Irene

AU - Watanabe, Kenichiro

AU - Derosa, Marisa

AU - Meyers, Rebecka

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction Contemporary state-of-the-art management of cancer is increasingly defined by individualized treatment strategies. For very rare tumors, like hepatoblastoma, the development of biologic markers, and the identification of reliable prognostic risk factors for tailoring treatment, remains very challenging. The Children's Hepatic tumors International Collaboration (CHIC) is a novel international response to this challenge. Methods Four multicenter trial groups in the world, who have performed prospective controlled studies of hepatoblastoma over the past two decades (COG; SIOPEL; GPOH; and JPLT), joined forces to form the CHIC consortium. With the support of the data management group CINECA, CHIC developed a centralized online platform where data from eight completed hepatoblastoma trials were merged to form a database of 1605 hepatoblastoma cases treated between 1988 and 2008. The resulting dataset is described and the relationships between selected patient and tumor characteristics, and risk for adverse disease outcome (event-free survival; EFS) are examined. Results Significantly increased risk for EFS-event was noted for advanced PRETEXT group, macrovascular venous or portal involvement, contiguous extrahepatic disease, primary tumor multifocality and tumor rupture at enrollment. Higher age (≥8 years), low AFP (<100 ng/ml) and metastatic disease were associated with the worst outcome. Conclusion We have identified novel prognostic factors for hepatoblastoma, as well as confirmed established factors, that will be used to develop a future common global risk stratification system. The mechanics of developing the globally accessible web-based portal, building and refining the database, and performing this first statistical analysis has laid the foundation for future collaborative efforts. This is an important step for refining of the risk based grouping and approach to future treatment stratification, thus we think our collaboration offers a template for others to follow in the study of rare tumors and diseases.

AB - Introduction Contemporary state-of-the-art management of cancer is increasingly defined by individualized treatment strategies. For very rare tumors, like hepatoblastoma, the development of biologic markers, and the identification of reliable prognostic risk factors for tailoring treatment, remains very challenging. The Children's Hepatic tumors International Collaboration (CHIC) is a novel international response to this challenge. Methods Four multicenter trial groups in the world, who have performed prospective controlled studies of hepatoblastoma over the past two decades (COG; SIOPEL; GPOH; and JPLT), joined forces to form the CHIC consortium. With the support of the data management group CINECA, CHIC developed a centralized online platform where data from eight completed hepatoblastoma trials were merged to form a database of 1605 hepatoblastoma cases treated between 1988 and 2008. The resulting dataset is described and the relationships between selected patient and tumor characteristics, and risk for adverse disease outcome (event-free survival; EFS) are examined. Results Significantly increased risk for EFS-event was noted for advanced PRETEXT group, macrovascular venous or portal involvement, contiguous extrahepatic disease, primary tumor multifocality and tumor rupture at enrollment. Higher age (≥8 years), low AFP (<100 ng/ml) and metastatic disease were associated with the worst outcome. Conclusion We have identified novel prognostic factors for hepatoblastoma, as well as confirmed established factors, that will be used to develop a future common global risk stratification system. The mechanics of developing the globally accessible web-based portal, building and refining the database, and performing this first statistical analysis has laid the foundation for future collaborative efforts. This is an important step for refining of the risk based grouping and approach to future treatment stratification, thus we think our collaboration offers a template for others to follow in the study of rare tumors and diseases.

KW - Chemotherapy

KW - Hepatoblastoma

KW - Pathology

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84948449764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948449764&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.09.023

DO - 10.1016/j.ejca.2015.09.023

M3 - Article

C2 - 26655560

AN - SCOPUS:84948449764

VL - 52

SP - 92

EP - 101

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -